Trial Details

Not Recruiting
Basic Information
Clinical ID c5515
Identifier ACTRN12607000617460
Trial Title Phase IIa examination of the effect of oral dosing of NV-52 on surrogate markers of inflammatory bowel disease (IBD) in patients with stable disease but with a consistent abnormality in one or more surrogate marker.
Trial URL Visit Original Page
Study Information
Study Results

NULL
Conditions Crohn's disease and Ulcerative Colitis; Crohn's disease and Ulcerative Colitis;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointestinal - Inflammatory bowel disease
Interventions NV-52 will be administered orally, once daily at a dose of 50mg/day for 4 weeks.
Participant Information
Sponsor Novogen Research Pty Ltd
City NULL
Country/Region Australia
Enrollment Criteria
Sex Requirement ALL
Age Requirement NULL
Study Design
Study Type Interventional
Phase PHASE2
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL